JPWO2021237110A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021237110A5 JPWO2021237110A5 JP2022571133A JP2022571133A JPWO2021237110A5 JP WO2021237110 A5 JPWO2021237110 A5 JP WO2021237110A5 JP 2022571133 A JP2022571133 A JP 2022571133A JP 2022571133 A JP2022571133 A JP 2022571133A JP WO2021237110 A5 JPWO2021237110 A5 JP WO2021237110A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- composition according
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029085P | 2020-05-22 | 2020-05-22 | |
| US63/029,085 | 2020-05-22 | ||
| US202063066705P | 2020-08-17 | 2020-08-17 | |
| US63/066,705 | 2020-08-17 | ||
| US202063071264P | 2020-08-27 | 2020-08-27 | |
| US63/071,264 | 2020-08-27 | ||
| US202063088147P | 2020-10-06 | 2020-10-06 | |
| US63/088,147 | 2020-10-06 | ||
| US202063121088P | 2020-12-03 | 2020-12-03 | |
| US63/121,088 | 2020-12-03 | ||
| US202163144939P | 2021-02-02 | 2021-02-02 | |
| US63/144,939 | 2021-02-02 | ||
| EP21315068 | 2021-04-21 | ||
| EP21315068.3 | 2021-04-21 | ||
| PCT/US2021/033693 WO2021237110A1 (en) | 2020-05-22 | 2021-05-21 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023527775A JP2023527775A (ja) | 2023-06-30 |
| JPWO2021237110A5 true JPWO2021237110A5 (https=) | 2024-05-28 |
| JP2023527775A5 JP2023527775A5 (https=) | 2024-05-28 |
Family
ID=76444669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571133A Pending JP2023527775A (ja) | 2020-05-22 | 2021-05-21 | Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250154267A2 (https=) |
| EP (1) | EP4153300A1 (https=) |
| JP (1) | JP2023527775A (https=) |
| KR (1) | KR20230015965A (https=) |
| CN (1) | CN115768516A (https=) |
| AU (1) | AU2021277398A1 (https=) |
| BR (1) | BR112022022235A2 (https=) |
| CA (1) | CA3174431A1 (https=) |
| IL (1) | IL298257A (https=) |
| MX (1) | MX2022014440A (https=) |
| WO (1) | WO2021237110A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| KR102695088B1 (ko) | 2014-02-28 | 2024-08-16 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| ES2994774T3 (en) | 2016-09-01 | 2025-01-31 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist |
| BR112020020387A2 (pt) | 2018-05-13 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| JP7836754B2 (ja) | 2019-08-05 | 2026-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法 |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| AU2023259352A1 (en) * | 2022-04-26 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Transcriptome analysis for treating inflammation |
| WO2024011251A1 (en) * | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
| CN121001741A (zh) | 2023-03-27 | 2025-11-21 | 瑞泽恩制药公司 | 用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法 |
| WO2025221247A1 (en) * | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| MXPA06004853A (es) | 2003-11-07 | 2006-07-06 | Immunex Corp | Anticuerpos que se aglutinan al receptor 4 de interleucina. |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| PH12016502073B1 (en) * | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TWI634900B (zh) * | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| KR102460040B1 (ko) * | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| TWI728172B (zh) * | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| IL315556A (en) * | 2017-08-04 | 2024-11-01 | Regeneron Pharma | Methods for treating active eosinophilic esophagitis |
| US11053309B2 (en) * | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| JP2021514513A (ja) * | 2018-02-21 | 2021-06-10 | アデア ファーマシューティカルズ，ユーエス，エル．ピー． | 好酸球性食道炎を管理する方法 |
| CN112261954B (zh) * | 2018-06-14 | 2025-06-24 | 味之素株式会社 | 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐 |
| KR102330596B1 (ko) | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
-
2021
- 2021-05-21 JP JP2022571133A patent/JP2023527775A/ja active Pending
- 2021-05-21 CA CA3174431A patent/CA3174431A1/en active Pending
- 2021-05-21 CN CN202180036330.4A patent/CN115768516A/zh active Pending
- 2021-05-21 EP EP21732754.3A patent/EP4153300A1/en active Pending
- 2021-05-21 BR BR112022022235A patent/BR112022022235A2/pt unknown
- 2021-05-21 AU AU2021277398A patent/AU2021277398A1/en active Pending
- 2021-05-21 MX MX2022014440A patent/MX2022014440A/es unknown
- 2021-05-21 US US17/327,504 patent/US20250154267A2/en active Pending
- 2021-05-21 IL IL298257A patent/IL298257A/en unknown
- 2021-05-21 WO PCT/US2021/033693 patent/WO2021237110A1/en not_active Ceased
- 2021-05-21 KR KR1020227045054A patent/KR20230015965A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021237110A5 (https=) | ||
| JP6306588B2 (ja) | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 | |
| CN105517570B (zh) | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 | |
| JP2016523863A5 (https=) | ||
| CN115768516A (zh) | 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法 | |
| JP2020500152A5 (https=) | ||
| JP2022160685A5 (https=) | ||
| JP2024174962A5 (https=) | ||
| IL316408A (en) | A safe and effective method for treating psoriasis with a specific anti-IL23 antibody | |
| US20200206227A1 (en) | Tyrosine kinase inhibitor formulations for the treatment of mast cell-mediated inflammatory diseases and methods of use thereof | |
| JP2024016237A5 (https=) | ||
| JP2020502261A5 (https=) | ||
| Stokes et al. | Rationale for new treatments aimed at IgE immunomodulation | |
| JPWO2019222055A5 (https=) | ||
| JP2025072440A5 (https=) | ||
| JPWO2017172771A5 (https=) | ||
| CN1612751A (zh) | 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗 | |
| JP2020529434A5 (https=) | ||
| JPWO2021026205A5 (https=) | ||
| JP6898421B2 (ja) | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 | |
| JP2020073525A5 (https=) | ||
| JPWO2021195530A5 (https=) | ||
| CN115942933A (zh) | 用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物 | |
| JP2005526022A5 (ja) | 関節リウマチの処置 | |
| CN119546337A (zh) | 通过施用il-4r拮抗剂治疗小儿嗜酸性粒细胞性食管炎的方法 |